PT2408453T - Formulações oftálmicas de cetirizina e métodos de utilização - Google Patents

Formulações oftálmicas de cetirizina e métodos de utilização

Info

Publication number
PT2408453T
PT2408453T PT107539272T PT10753927T PT2408453T PT 2408453 T PT2408453 T PT 2408453T PT 107539272 T PT107539272 T PT 107539272T PT 10753927 T PT10753927 T PT 10753927T PT 2408453 T PT2408453 T PT 2408453T
Authority
PT
Portugal
Prior art keywords
cetirizine
methods
ophthalmic formulations
ophthalmic
formulations
Prior art date
Application number
PT107539272T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Nicox Ophthalmics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox Ophthalmics Inc filed Critical Nicox Ophthalmics Inc
Publication of PT2408453T publication Critical patent/PT2408453T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4174Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT107539272T 2009-03-17 2010-03-15 Formulações oftálmicas de cetirizina e métodos de utilização PT2408453T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16100609P 2009-03-17 2009-03-17
US17485009P 2009-05-01 2009-05-01

Publications (1)

Publication Number Publication Date
PT2408453T true PT2408453T (pt) 2022-04-05

Family

ID=42738180

Family Applications (2)

Application Number Title Priority Date Filing Date
PT211797519T PT3943069T (pt) 2009-03-17 2010-03-15 Formulações oftálmicas de cetirizina e métodos de utilização
PT107539272T PT2408453T (pt) 2009-03-17 2010-03-15 Formulações oftálmicas de cetirizina e métodos de utilização

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT211797519T PT3943069T (pt) 2009-03-17 2010-03-15 Formulações oftálmicas de cetirizina e métodos de utilização

Country Status (8)

Country Link
US (8) US9254286B2 (enExample)
EP (2) EP3943069B1 (enExample)
JP (8) JP6033677B2 (enExample)
CA (1) CA2755679C (enExample)
ES (2) ES3014823T3 (enExample)
MX (1) MX2011009802A (enExample)
PT (2) PT3943069T (enExample)
WO (1) WO2010107689A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011009802A (es) * 2009-03-17 2011-11-02 Aciex Therapeutics Inc Formulaciones oftalmicas de cetirizina y metodos de uso.
US8569273B2 (en) * 2009-03-17 2013-10-29 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
US20110105450A1 (en) * 2009-06-05 2011-05-05 Aciex Therapeutics, Inc. Ophthalmic formulations of fluticasone and methods of use
US10156386B2 (en) 2010-05-12 2018-12-18 Brooks Automation, Inc. System and method for cryogenic cooling
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠(olopatadine)眼用組成物
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
ES2727474T3 (es) 2012-05-08 2019-10-16 Nicox Ophthalmics Inc Nanocristales de propionato de fluticasona
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
WO2018147409A1 (ja) * 2017-02-13 2018-08-16 日東メディック株式会社 水性点眼点鼻用組成物
MY205909A (en) 2017-06-08 2024-11-20 Eye Therapies Llc Low-dose brimonidine combinations and uses thereof
WO2019140403A1 (en) * 2018-01-15 2019-07-18 Seattle Gummy Company Semi-solid anti-histamine compositions and methods of making and using thereof
CN113712908A (zh) * 2020-05-25 2021-11-30 南京帝昌医药科技有限公司 一种用于治疗过敏性结膜炎的组合物其制备方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US440779A (en) 1890-11-18 Edward smith axd frederick smith
US541989A (en) 1895-07-02 Joseph h
US452535A (en) 1891-05-19 Ehregott theodore winkler
US569855A (en) 1896-10-20 Alvor butterfield
US518882A (en) 1894-04-24 Mary p
US610373A (en) 1898-09-06 Michele signorastbi
US643692A (en) 1899-09-27 1900-02-20 Bernard H Speckbauch Printing-press.
US682794A (en) 1899-12-19 1901-09-17 Friedrich August Gasch Process of obtaining zinc solutions free from iron and manganese compounds.
US664960A (en) 1900-09-05 1901-01-01 John A Hill Oil-separator and automatic regulating-valve for refrigerating systems.
FI75816C (fi) * 1981-02-06 1988-08-08 Ucb Sa Foerfarande foer framstaellning av terapeutiskt aktiv 2-/4-(difenylmetyl)-1-piperazinyl/-aettiksyror eller dess amid.
US4407791A (en) 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US5188826A (en) 1988-02-08 1993-02-23 Insite Vision Incorporated Topical ophthalmic suspensions
AU636685B2 (en) 1989-12-18 1993-05-06 Alcon Laboratories, Inc. Compositions of antiallergics and antihistamines and methods for their use
EP0950412A3 (en) 1992-09-24 2001-05-16 Sepracor, Inc. Compositions for treating allergic disorders using (-) cetirizine
TW401300B (en) 1992-12-25 2000-08-11 Senju Pharma Co Antiallergic composition for ophthalmic or nasal use
WO1997046243A1 (en) 1996-06-04 1997-12-11 The Procter & Gamble Company A nasal spray containing an intranasal steroid and an antihistamine
PL191073B1 (pl) 1996-08-16 2006-03-31 Schering Corp Zastosowanie kombinacji antagonistów receptorów histaminowych H1 i H3
EP0903151A1 (en) * 1997-09-22 1999-03-24 ASTA Medica Aktiengesellschaft Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms
US6103735A (en) 1998-10-09 2000-08-15 Schering Corporation Composition and method for treating allergic diseases
EP1242090A4 (en) 1999-11-18 2004-02-11 Alcon Inc USE OF AN H1 ANTAGONIST AND A SAFE STEROID IN THE TREATMENT OF EYE CONDITIONS
DE10007203A1 (de) 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
JP2002025272A (ja) 2000-07-10 2002-01-25 Sharp Corp 半導体記憶装置およびその評価方法
AR035509A1 (es) 2000-12-21 2004-06-02 Alcon Inc Solucion de lagrimas artificiales mejorada que contiene una combinacion de tres emolientes y el uso de dicha solucion para la fabricacion de un medicamento
US7243343B2 (en) 2001-04-10 2007-07-10 International Business Machines Corporation Method, compiler and platform independent framework for parsing and generating data structures
US6985573B2 (en) 2001-04-13 2006-01-10 General Instrument Corporation Customer premises equipment that can support multiple call control languages or multiple call agents
US6592896B2 (en) 2001-08-06 2003-07-15 The Quigley Corporation Medicinal composition and method of using it
US6827946B2 (en) 2001-12-05 2004-12-07 Collegium Pharmaceutical, Inc. Compositions containing both sedative and non-sedative antihistamines
ATE317268T1 (de) 2001-12-05 2006-02-15 Alcon Inc Verwendung eines h1-antagonisten und von rimexolon als sicheres steroid zur behandlung von rhinitis
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US20040019882A1 (en) 2002-07-26 2004-01-29 Haydt Robert J. Scalable data communication model
RU2220740C1 (ru) 2002-08-30 2004-01-10 Гапонюк Петр Яковлевич Средство для лечения аллергического ринита и аллергического конъюнктивита
JP2004168709A (ja) 2002-11-20 2004-06-17 Nidek Co Ltd 抗アレルギー点眼点鼻用組成物
US20040198828A1 (en) 2003-01-17 2004-10-07 Abelson Mark B. Combinational use of long-acting and short-acting anti-histamines for ocular allergies
US20050090527A1 (en) 2003-01-28 2005-04-28 Schering Corporation Combination of H1, H3 and H4 receptor antagonists for treatment of allergic and non-allergic pulmonary inflammation, congestion and allergic rhinitis
WO2004069338A1 (en) 2003-01-31 2004-08-19 Schering Corporation Use of combinations of h1 and h3 histamine receptor antagonists for the preparation of a medicament for the treatment of allergic skin and allergic ocular conditions
US20050023974A1 (en) 2003-08-01 2005-02-03 Universal Display Corporation Protected organic electronic devices and methods for making the same
EP1663694A1 (de) 2003-09-23 2006-06-07 DaimlerChrysler AG Verfahren und vorrichtung zur erkennung von spurwechselvorg ngen f r ein fahrzeug
US20060263350A1 (en) 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
WO2005030331A1 (en) 2003-09-26 2005-04-07 Fairfield Clinical Trials, Llc Combination antihistamine medication
US20050239745A1 (en) 2004-03-03 2005-10-27 Ophthalmic Research Associates, Inc. Novel topical ophthalmic formulations
US20050255154A1 (en) 2004-05-11 2005-11-17 Lena Pereswetoff-Morath Method and composition for treating rhinitis
US8372814B2 (en) * 2004-06-07 2013-02-12 Ista Pharmaceuticals, Inc. Ophthalmic formulations and uses thereof
PE20060484A1 (es) 2004-07-14 2006-07-06 Ucb Farchim Sa Preparaciones farmaceuticas liquidas que comprenden un compuesto de benzhidril piperizina
JP3897777B2 (ja) 2004-07-23 2007-03-28 株式会社半導体理工学研究センター パルスベース通信システム
WO2006010294A1 (en) 2004-07-26 2006-02-02 Quanta Display Inc. Liquid crystal display device
US7337789B2 (en) 2004-07-27 2008-03-04 Minel Kupferberg Cleaning apparatus for exhaust system and method
US7307535B2 (en) 2004-07-27 2007-12-11 Datamars S.A. Air coil RF transponder and method of making same
CA2538865C (en) 2004-07-30 2011-03-29 Research In Motion Limited Method and apparatus for provisioning a communications client on a host device
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US8003127B2 (en) 2005-03-23 2011-08-23 Elan Pharma International Limited Nanoparticulate corticosteroid and antihistamine formulations methods of making, and methods of administering thereof
JP2007012937A (ja) 2005-06-30 2007-01-18 Seiko Epson Corp 表示ドライバ
PT1919450E (pt) * 2005-09-01 2014-09-10 Meda Ab Composição lipossomal contendo anti-histamínico e corticosteróide e sua utilização para a preparação de um medicamento para o tratamento de rinite e distúrbios relacionados
BRPI0710085B8 (pt) 2006-03-31 2021-05-25 Vistakon Pharmaceutical Llc composições oftálmicas e seus kits
US20080008592A1 (en) 2006-06-27 2008-01-10 Societe De Commercialisation Des Produits De La Recherche Appliquee - Socpra-Sc Method and apparatus for controlling tonal noise from subsonic axial fans
WO2009003199A1 (en) * 2007-06-28 2008-12-31 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
KR100834625B1 (ko) 2006-07-27 2008-06-02 삼성전자주식회사 비디오 인코딩 데이터율 제어를 위한 실시간 장면 전환검출 방법
CA2664790C (en) 2006-09-29 2015-11-24 Johnson & Johnson Vision Care, Inc. Methods and ophthalmic devices used in the treatment of ocular allergies
TW200902025A (en) * 2007-04-11 2009-01-16 Alcon Res Ltd Use of an inhibitor of TNF α plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
MX2011009802A (es) * 2009-03-17 2011-11-02 Aciex Therapeutics Inc Formulaciones oftalmicas de cetirizina y metodos de uso.

Also Published As

Publication number Publication date
JP6449202B2 (ja) 2019-01-09
US9254286B2 (en) 2016-02-09
JP2015007136A (ja) 2015-01-15
CA2755679C (en) 2017-09-12
JP2020117544A (ja) 2020-08-06
US10987352B2 (en) 2021-04-27
US9750684B2 (en) 2017-09-05
US11617749B2 (en) 2023-04-04
JP6033677B2 (ja) 2016-11-30
EP3943069B1 (en) 2024-11-27
ES2910374T3 (es) 2022-05-12
JP2012520882A (ja) 2012-09-10
JP2018141022A (ja) 2018-09-13
US11918573B2 (en) 2024-03-05
JP2016190878A (ja) 2016-11-10
US20170182035A1 (en) 2017-06-29
US10675279B2 (en) 2020-06-09
US20130252971A1 (en) 2013-09-26
PT3943069T (pt) 2025-02-21
JP6144393B2 (ja) 2017-06-07
JP6893573B2 (ja) 2021-06-23
US20160106666A1 (en) 2016-04-21
EP2408453B1 (en) 2022-01-05
US20100240625A1 (en) 2010-09-23
WO2010107689A1 (en) 2010-09-23
ES3014823T3 (en) 2025-04-25
US9993471B2 (en) 2018-06-12
JP2021138760A (ja) 2021-09-16
US20200297719A1 (en) 2020-09-24
CA2755679A1 (en) 2010-09-23
EP3943069A1 (en) 2022-01-26
EP2408453A1 (en) 2012-01-25
US8829005B2 (en) 2014-09-09
MX2011009802A (es) 2011-11-02
US20200405711A1 (en) 2020-12-31
JP2020117545A (ja) 2020-08-06
JP7088980B2 (ja) 2022-06-21
US20180280383A1 (en) 2018-10-04
JP2016190879A (ja) 2016-11-10
EP2408453A4 (en) 2013-08-28
US20210290617A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
EP2437743A4 (en) OPHTHALMIC FORMULATIONS OF FLUTICASONE AND METHODS OF USE
PT3943069T (pt) Formulações oftálmicas de cetirizina e métodos de utilização
EP2408302A4 (en) OPHTALMIC FORMULATIONS OF KTOTICENE AND METHODS OF USE
IL256924B (en) Prebiotic formulations and methods of using them
EP2437602A4 (en) OPHTHALMIC FORMULATIONS, METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR THEIR USE
EP2448581A4 (en) THERAPEUTIC COMPOSITIONS AND METHODS OF USE THEREOF
GB2509446B (en) Patient interface and aspects thereof
GB2494493B (en) Patient interface and aspects thereof
IL219974A0 (en) Therapeutic compounds and related methods of use
EP2637684A4 (en) BUFFERED OPHTHALMIC COMPOSITIONS AND USER METHOD THEREFOR
EP2547340A4 (en) OPHTHALMIC FORMULATIONS OF CETIRICINE AND METHOD FOR THEIR USE
EP2449102A4 (en) ARGINASE FORMULATIONS AND METHODS
EP2464227A4 (en) COMPOUNDS AND METHODS OF USE
IL236830A0 (en) Diazahomoredene derivatives and methods of using them
GB0920258D0 (en) New medical agents and use thereof
ZA201202892B (en) Ophthalmic formulation and method of manufacture thereof
IL217135A0 (en) Stabilized herbicidal formulations and methods of use
EP2381950A4 (en) COMPOSITIONS AND METHOD FOR THEIR USE
IL226134A0 (en) Ophthalmic preparations with buffer and methods for their preparation
HK1167143A (en) Therapeutic compositions and related methods of use
HK1166236A (en) Prebiotic formulations and methods of use
GB0914356D0 (en) Ophthalmic formulations